Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference21 articles.
1. Lambert G, Sjouke B, Choque B, Kastelein JJP, Hovingh GK. The PCSK9 decade. J Lipid Res. 2012;53:2515–24.
2. Lunven C, Paehler T, Poitiers F, Brunet A, Rey J, Hanotin C, et al. A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects. Cardiovasc Ther. 2014;32:297–301.
3. European Medecines Agency. Praluent. https://www.ema.europa.eu/en/medicines/human/EPAR/praluent. Accessed 1 Jun 2022.
4. FDA USF and DA. Drug Approval Package: Praluent (alirocumab). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/125559Orig1s014TOC.cfm. Accessed 1 Jun 2022.
5. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489–99.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献